Sanofi’s MenQuadfi approved in the EU for use in infants from age six weeks against invasive meningococcal diseaseParis, August 4, 2026. Sanofi today announced that the European Commission (EC) has approved an extension of the indication for MenQuadfi (Meningococcal Group A, C, W and Y conjugate va…
Sanofi SA Sponsored ADR (EURONEXT:SAN) beat Q2 estimates with stronger EPS, operating income, sales and free cash flow, then announced a tighter R&D focus and portfolio review that may cut programs (amlitelimab, itepekimab, balinatunfib) to prioritize high‑science, high‑need projects.Previous Week…
Sanofi SA Sponsored ADR (SAN) lifted its 2026 outlook: now targeting about 10% CER sales growth and forecasted business EPS to rise slightly faster than sales on a CER basis.Sanofi
Q2 2026 saw 17.8% sales growth at CER and a 33.3% rise in business EPS, driven by strong pharma launches and Dupixent. Upgraded 2026 guidance expects ~10% sales growth at CER, with business EPS outpacing sales. Significant pipeline progress and capital returns were reported.Original document: Sanof…
RNS Number : 0512O Malin Corporation PLC 27 July 2026 .Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviewsDublin-Ireland, 27 July 2026: Malin Corporation plc (Euronext Growth Dublin:MLC) (Malin), a company investing in highly innovative life sc…
Sanofi (EURONEXT:SAN) halted amlitel imab for atopic dermatitis over efficacy and safety concerns and won’t seek approval, even as a Phase 2 celiac readout is expected H2 2026; leadership changes with Belen Garijo as CEO and Paulo Fontoura heading R&D signal a strategic pipeline reassessment.Previo…
Sanofi evolves its Executive Committee to support its next strategic chapterParis, July 21, 2026. Sanofi today announced an evolution of its Executive Committee, bringing together a focused leadership team across its businesses, scientific organization and key global functions as the company contin…
Sanofi (EURONEXT:SAN) reported Phase 3 Baby-COMET success for Nexviazyme in infantile-onset Pompe—meeting primary and secondary endpoints, well tolerated with no serious treatment-related AEs—and said a U.S. label filing is expected in H2 2026 while Q2 results arrive July 30, 2026.Previous Week Rec…
